Table 4.
Multivariable analysis of IDH wild-type lower-grade gliomas stratified by “molecular grade” and MYB amplification
| HR | (95% CI) | P | |
|---|---|---|---|
| Agea | 1.02 | (0.99–1.05) | 0.25 |
| Histologic Type | |||
| Oligodendroglioma | 1 | ||
| Oligoastrocytoma | 1.51 | (0.33–6.97) | 0.59 |
| Astrocytoma | 0.77 | (0.20–2.90) | 0.7 |
| Histologic Grade | |||
| II | 1 | ||
| III | 12 | (4.68–30.8)* | <0.001 |
| Total Resection | |||
| Yes | 1 | ||
| No | 2.51 | (1.32–4.79)* | 0.004 |
| Tumor Location | |||
| Nonmidline | 1 | ||
| Midline | 1.76 | (0.88–3.53) | 0.21 |
| Effect of MYB in Molecular Subgroup | |||
| Molecularly high gradeb | 1 | ||
| Molecularly lower grade,cMYB non-amp | 0.26 | (0.13–0.5)* | <0.001 |
| Molecularly lower grade,cMYB amp | 0.23 | (0.08–0.68)* | 0.008 |
aAge is a continuous variable; amp, amplified; non-amp, non-amp lified; *denotes P < 0.05. bIDH wild-type lower-grade gliomas harboring either EGFR amplification, H3F3A-K27M, or TERT promoter mutation. cIDH wild-type lower-grade gliomas lacking EGFR amplification, H3F3A mutation, and TERT promoter mutation.